Last reviewed · How we verify
Reducing Antibiotics treatment duration
This is a clinical trial strategy to optimize antibiotic treatment by reducing the duration of therapy while maintaining clinical efficacy and safety outcomes.
This is a clinical trial strategy to optimize antibiotic treatment by reducing the duration of therapy while maintaining clinical efficacy and safety outcomes. Used for Bacterial infections requiring antibiotic therapy (specific indication dependent on trial design).
At a glance
| Generic name | Reducing Antibiotics treatment duration |
|---|---|
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rather than a traditional drug, this represents a therapeutic approach being studied in Phase 3 trials by the University of Oxford to determine whether shorter courses of antibiotics can achieve equivalent clinical outcomes compared to standard longer-duration regimens. The mechanism relies on identifying optimal treatment duration thresholds that balance pathogen eradication with minimizing unnecessary antibiotic exposure, thereby reducing resistance development and adverse effects.
Approved indications
- Bacterial infections requiring antibiotic therapy (specific indication dependent on trial design)
Common side effects
- Antibiotic-related adverse events (varies by antibiotic class used)
- Treatment failure or relapse risk
Key clinical trials
- Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia (NA)
- Folate Treatment to Reduce Death Risk in the Year After Infection-Related Acute Kidney Injury (EARLY_PHASE1)
- Reducing Overuse of Antibiotics With Decision Support (NA)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
- Trial of Reducing Inpatient Antibiotic Durations in Children (PHASE4)
- Facial Muscle Exercises vs Fractional Microneedling Radiofrequency for Facial Rejuvenation (NA)
- Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE) (NA)
- Topical Vancomycin for Neurosurgery Wound Prophylaxis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reducing Antibiotics treatment duration CI brief — competitive landscape report
- Reducing Antibiotics treatment duration updates RSS · CI watch RSS
- University of Oxford portfolio CI